Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew A Care

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Journal of Immunology (Baltimore, Md. : 1950)|July 1, 2016
Network Analysis Identifies Proinflammatory Plasma Cell Polarization for Secretion of ISG15 in Human AutoimmunityMatthew A Care, Sophie J Stephenson, Nicholas A Barnes, et al.
Nucleic Acids Research|May 31, 2014
SPIB and BATF provide alternate determinants of IRF4 occupancy in diffuse large B-cell lymphoma linked to disease heterogeneityMatthew A Care, Mario Cocco, Jon P Laye, et al.
The Journal of Allergy and Clinical Immunology|November 13, 2017
Biallelic interferon regulatory factor 8 mutation: A complex immunodeficiency syndrome with dendritic cell deficiency, monocytopenia, and immune dysregulationVenetia Bigley, Sheetal Maisuria, Urszula Cytlak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 8, 2018
Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to TherapyChulin Sha, Sharon Barrans, Francesco Cucco, et al.
Leukemia|December 18, 2019
Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hitFrancesco Cucco, Sharon Barrans, Chulin Sha, et al.
The Lancet. Oncology|April 6, 2019
Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trialAndrew Davies, Thomas E Cummin, Sharon Barrans, et al.
Genome Biology|February 7, 2024
IDHwt glioblastomas can be stratified by their transcriptional response to standard treatment, with implications for targeted therapyGeorgette Tanner, Rhiannon Barrow, Shoaib Ajaib, et al.
The Journal of Clinical Investigation|November 29, 2016
Biallelic mutations in IRF8 impair human NK cell maturation and functionEmily M Mace, Venetia Bigley, Justin T Gunesch, et al.
Cancer Cell|June 4, 2026
Pathogenesis of diffuse large B cell lymphoma proteogenotypesJulius C Enssle, Björn Häupl, Arber Qoku, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Journal of Immunology (Baltimore, Md. : 1950)|July 1, 2016
Network Analysis Identifies Proinflammatory Plasma Cell Polarization for Secretion of ISG15 in Human AutoimmunityMatthew A Care, Sophie J Stephenson, Nicholas A Barnes, et al.
Nucleic Acids Research|May 31, 2014
SPIB and BATF provide alternate determinants of IRF4 occupancy in diffuse large B-cell lymphoma linked to disease heterogeneityMatthew A Care, Mario Cocco, Jon P Laye, et al.
The Journal of Allergy and Clinical Immunology|November 13, 2017
Biallelic interferon regulatory factor 8 mutation: A complex immunodeficiency syndrome with dendritic cell deficiency, monocytopenia, and immune dysregulationVenetia Bigley, Sheetal Maisuria, Urszula Cytlak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 8, 2018
Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to TherapyChulin Sha, Sharon Barrans, Francesco Cucco, et al.
Leukemia|December 18, 2019
Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hitFrancesco Cucco, Sharon Barrans, Chulin Sha, et al.
The Lancet. Oncology|April 6, 2019
Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trialAndrew Davies, Thomas E Cummin, Sharon Barrans, et al.
Genome Biology|February 7, 2024
IDHwt glioblastomas can be stratified by their transcriptional response to standard treatment, with implications for targeted therapyGeorgette Tanner, Rhiannon Barrow, Shoaib Ajaib, et al.
The Journal of Clinical Investigation|November 29, 2016
Biallelic mutations in IRF8 impair human NK cell maturation and functionEmily M Mace, Venetia Bigley, Justin T Gunesch, et al.
Cancer Cell|June 4, 2026
Pathogenesis of diffuse large B cell lymphoma proteogenotypesJulius C Enssle, Björn Häupl, Arber Qoku, et al.
Pageof 3